Open AccessShould pediatric idiopathic hypercalciuria be treated with hypocalciuric agents?
Author(s) -
Maria Goretti Moreira Guimarães Penido,
Marcelo de Sousa Tavares
Publication year - 2021
Publication title -
world journal of nephrology
Language(s) - English
Resource type - Journals
ISSN - 2220-6124
DOI - 10.5527/wjn.v10.i4.47
Subject(s) - medicine , hypercalciuria , thiazide , creatinine , urology , body mass index , bone mineral , endocrinology , bone density , diuretic , calcium , osteoporosis
Hypercalciuria is the most common metabolic risk factor for calcium urolithiasis and is associated with bone loss in adult patients. Reduced bone mineral density (BMD) was already described in idiopathic hypercalciuria (IH) children, but the precise mechanisms of bone loss or inadequate bone mass gain remain unknown. Life-long hypercalciuria might be considered a risk to change bone structure and determine low bone mass throughout life. The peak of bone mass should occur without interferences. A beneficial effect of citrate formulations and thiazides on bone mass in adult and pediatric patients with IH have been shown.